• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚太肝病学会肝癌共识建议。

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

出版信息

Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.

DOI:10.1007/s12072-010-9165-7
PMID:20827404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2900561/
Abstract

INTRODUCTION

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations.

METHODS

The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements.

RESULTS

Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

摘要

简介

亚太肝脏研究学会(APASL)于 2008 年 12 月召集了一个国际工作组,负责制定肝细胞癌(HCC)管理的共识建议。

方法

工作组由来自亚太地区的专家级肝病学家、肝胆外科医生、放射科医生和肿瘤学家组成,他们在 2008 年 12 月 4 日于印度尼西亚巴厘岛举行的共识会议之前,被要求起草草案。根据牛津循证医学方法系统,对现有证据的质量和建议的强度进行排名,分别从 1(最高)到 5(最低)和从 A(最强)到 D(最弱)。

结果

共识会议的参与者评估了引用研究的质量,并为建议声明分配了等级。最终的建议在印度尼西亚巴厘岛举行的第四届 APASL 病毒性 HCC 专题会议上提出,并得到了会议参与者的批准。

相似文献

1
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.亚太肝病学会肝癌共识建议。
Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.
2
APASL consensus statements and management algorithms for hepatitis C virus infection.亚太肝脏研究学会丙型肝炎病毒感染共识声明及管理算法
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
3
APASL consensus statements and recommendation on treatment of hepatitis C.亚太肝脏研究学会关于丙型肝炎治疗的共识声明与建议
Hepatol Int. 2016 Sep;10(5):702-26. doi: 10.1007/s12072-016-9717-6. Epub 2016 Apr 29.
4
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.亚太肝脏研究学会关于丙型肝炎预防、流行病学及实验室检测的共识声明与建议
Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.
5
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).急性慢性肝衰竭:亚太肝病学会(APASL)的共识建议。
Hepatol Int. 2009 Mar;3(1):269-82. doi: 10.1007/s12072-008-9106-x. Epub 2008 Nov 20.
6
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL).肝纤维化:亚太肝病学会(APASL)的共识建议。
Hepatol Int. 2009 Jun;3(2):323-33. doi: 10.1007/s12072-008-9114-x. Epub 2008 Dec 4.
7
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.亚太肝脏研究协会(APASL)关于肝纤维化侵入性和非侵入性评估的共识指南:2016年更新版
Hepatol Int. 2017 Jan;11(1):1-30. doi: 10.1007/s12072-016-9760-3. Epub 2016 Oct 6.
8
Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver.原发性胃食管静脉曲张出血的预防:亚太肝病学会共识推荐。
Hepatol Int. 2008 Dec;2(4):429-39. doi: 10.1007/s12072-008-9096-8. Epub 2008 Sep 5.
9
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014.《急性-on-慢性肝衰竭:亚太肝脏研究协会(APASL)2014年共识推荐》
Hepatol Int. 2014 Oct;8(4):453-71. doi: 10.1007/s12072-014-9580-2. Epub 2014 Sep 26.
10
Consensus on extra-hepatic portal vein obstruction.肝外门静脉阻塞的共识
Liver Int. 2006 Jun;26(5):512-9. doi: 10.1111/j.1478-3231.2006.01269.x.

引用本文的文献

1
Cancer surveillance in biliary atresia patients with native liver survival: Standardizing monitoring and follow-up.对肝生存的胆道闭锁患者进行癌症监测:规范监测与随访。
Pediatr Surg Int. 2025 Jun 12;41(1):165. doi: 10.1007/s00383-025-06066-y.
2
Pan-Immune-Inflammation Value as a Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy.全免疫炎症值作为接受肝切除术的肝细胞癌患者的预后生物标志物
J Inflamm Res. 2025 May 20;18:6411-6425. doi: 10.2147/JIR.S521603. eCollection 2025.
3
Efficacy of repeat hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: a Systematic Review and meta-analysis.复发性肝细胞癌再次肝切除术与射频消融术的疗效比较:一项系统评价与荟萃分析
Front Oncol. 2025 Mar 26;15:1559491. doi: 10.3389/fonc.2025.1559491. eCollection 2025.
4
Variability of HCC Tumor Diameter and Density Measurements on Dynamic Contrast-Enhanced Computed Tomography.动态对比增强计算机断层扫描中肝癌肿瘤直径和密度测量的变异性
Tomography. 2025 Mar 19;11(3):36. doi: 10.3390/tomography11030036.
5
Optimizing Hepatocellular Carcinoma Screening: A Comparative Simulated Abbreviated MRI Protocol Study.优化肝细胞癌筛查:一项比较性模拟简化磁共振成像方案研究。
Cureus. 2025 Feb 7;17(2):e78711. doi: 10.7759/cureus.78711. eCollection 2025 Feb.
6
Adjuvant sorafenib for hepatocellular carcinoma after radiofrequency ablation versus radiofrequency ablation: analysis of its efficacy and safety.射频消融术后辅助索拉非尼治疗肝细胞癌与单纯射频消融治疗的疗效及安全性分析
Front Oncol. 2024 Dec 4;14:1383312. doi: 10.3389/fonc.2024.1383312. eCollection 2024.
7
Blood biomarkers of hepatocellular carcinoma: a critical review.肝细胞癌的血液生物标志物:一项批判性综述。
Front Cell Dev Biol. 2024 Nov 22;12:1489836. doi: 10.3389/fcell.2024.1489836. eCollection 2024.
8
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.索拉非尼治疗经肝动脉化疗栓塞治疗抵抗的中期肝细胞癌患者的疗效。
BMC Cancer. 2024 Nov 28;24(1):1466. doi: 10.1186/s12885-024-13199-1.
9
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.2024年亚太肝脏研究学会肝细胞癌全身治疗临床实践指南
Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.
10
Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy.肝切除术后 Child-Pugh B7 或 B8 的肝癌患者辅助 TACE 的生存获益。
BMC Cancer. 2024 Oct 8;24(1):1241. doi: 10.1186/s12885-024-13028-5.

本文引用的文献

1
Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.肿瘤标志物诊断肝细胞癌的准确性:系统评价。
Hepatol Int. 2008 Mar;2(1):17-30. doi: 10.1007/s12072-007-9038-x. Epub 2007 Dec 29.
2
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性:一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
3
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.慢性乙型肝炎患者发生肝细胞癌的独立危险因素及预测评分
J Hepatol. 2009 Jan;50(1):80-8. doi: 10.1016/j.jhep.2008.07.023. Epub 2008 Sep 21.
4
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.丙型肝炎相关晚期肝病中肝细胞癌的发病率及相关危险因素
Gastroenterology. 2009 Jan;136(1):138-48. doi: 10.1053/j.gastro.2008.09.014. Epub 2008 Sep 18.
5
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.奥沙利铂用于不可切除、转移性或复发性肝细胞癌患者的II期研究:一项加利福尼亚癌症联盟试验
Am J Clin Oncol. 2008 Aug;31(4):317-22. doi: 10.1097/COC.0b013e318162f57d.
6
Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications.经动脉化疗栓塞治疗肝细胞癌的综述:姑息性、联合性、新辅助性、桥接性和症状性适应证。
Eur J Radiol. 2009 Dec;72(3):505-16. doi: 10.1016/j.ejrad.2008.08.007. Epub 2008 Oct 2.
7
Molecular targeted therapies in hepatocellular carcinoma.肝细胞癌的分子靶向治疗
Hepatology. 2008 Oct;48(4):1312-27. doi: 10.1002/hep.22506.
8
Laparoscopic versus open liver segmentectomy: prospective, case-matched, intention-to-treat analysis of clinical outcomes and cost effectiveness.腹腔镜与开放肝段切除术:临床结局和成本效益的前瞻性、病例匹配、意向性分析
Surg Endosc. 2008 Dec;22(12):2564-70. doi: 10.1007/s00464-008-0110-y. Epub 2008 Sep 24.
9
Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress.十全大补汤对肝癌发生的保护作用是通过抑制库普弗细胞诱导的氧化应激来介导的。
Int J Cancer. 2008 Dec 1;123(11):2503-11. doi: 10.1002/ijc.23828.
10
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.乙型肝炎病毒基因型和突变体与肝细胞癌风险之间的关联。
J Natl Cancer Inst. 2008 Aug 20;100(16):1134-43. doi: 10.1093/jnci/djn243. Epub 2008 Aug 11.